NCT04774068 2025-01-17Romidepsin and Parsaclisib for the Treatment of Relapsed or Refractory T-Cell LymphomasOhio State University Comprehensive Cancer CenterPhase 1 Completed5 enrolled
NCT02646748 2022-03-31Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid TumorsIncyte CorporationPhase 1 Completed159 enrolled